NCE-1 Intelligence & Market Opportunity

Hyrnuo

Sevabertinib

Anticancer

Oral Tablet

Hyrnuo (sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain activating mutations. It is prescribed after patients have received at least one prior systemic therapy. Hyrnuo works by blocking HER2-driven tumor growth and is taken twice daily with food.

Approval Date

19-Nov-25

NCE-1 Date

19-Nov-29

NCE Date

19-Nov-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

119

2032

149

Molecule profile

Details & specifications

Molecule

Sevabertinib

Innovator

BAYER HEALTHCARE PHARMACEUTICALS INC

Dosage Form

Oral Tablet

Strength

10 mg

Therapeutic Category

Anticancer

Usage

To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets